GlassScriptPhysician profile
Nader S Warra
NPI 1619187275
$145,911.26
in general payments reported to CMS, 2019-2025
72 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $9,361 · 2021: $20K · 2022: $3,181 · 2023: $14K · 2024: $29K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Food and Beverage: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Consulting Fee: $4,513 · Travel and Lodging: $1,831 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,365.00 |
| Food and Beverage | $12,986.15 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,782.50 |
| Consulting Fee | $4,512.50 |
| Travel and Lodging | $1,830.92 |
| Education | $130.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $30,674.27 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $27,441.40 | 2019-2025 | Ajovy, Austedo, Austedo Xr |
| Eisai INC. | $18,383.78 | 2019-2025 | |
| Genzyme Corporation | $16,559.07 | 2019-2025 | |
| Biogen, INC. | $9,687.81 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Mdd US Operations, LLC | $8,564.57 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $6,951.32 | 2022-2025 | Hyqvia, Gammagard |
| Avanir Pharmaceuticals, INC. | $5,901.42 | 2019-2022 | |
| Corium, LLC | $4,097.82 | 2023 | Adlarity |
| Novartis Pharmaceuticals Corporation | $2,701.75 | 2019-2025 | |
| Emd Serono, INC. | $2,343.48 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $1,567.83 | 2019-2025 | Botox, Ubrelvy, Qulipta |
| Ucb, INC. | $1,417.12 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Celgene Corporation | $979.79 | 2021-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $969.63 | 2019-2025 | Ingrezza, Ongentys |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $660.32 | 2019-2025 | Uplizna |
| Lundbeck LLC | $603.74 | 2019-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $550.39 | 2019-2025 | Ultomiris |
| Csl Behring | $545.59 | 2019-2025 | Hizentra, Kcentra, Privigen |
| E.R. Squibb & Sons, L.L.C. | $447.89 | 2020-2025 | Zeposia |
| Alnylam Pharmaceuticals INC. | $377.91 | 2019-2025 | Onpattro, Amvuttra |
| Genentech USA, INC. | $340.05 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Acorda Therapeutics, INC | $286.08 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $246.12 | 2020-2025 | |
| Grifols USA, LLC | $225.18 | 2019-2024 | Gamunex-C |
| Acadia Pharmaceuticals INC | $204.66 | 2019-2025 | Nuplazid |
| Sumitomo Pharma America, INC. | $186.71 | 2023-2024 | Aptiom |
| Allergan, INC. | $180.10 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $169.25 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $166.36 | 2021 | |
| Vanda Pharmaceuticals INC. | $162.98 | 2025 | Ponvory |
| Horizon Therapeutics Plc | $159.57 | 2021-2023 | Uplizna |
| Adamas Pharmaceuticals, INC. | $132.18 | 2019-2020 | |
| Sk Life Science, INC. | $128.26 | 2020-2025 | |
| Pfizer INC. | $124.80 | 2021-2025 | |
| Livanova USA, INC. | $112.62 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Supernus Pharmaceuticals, INC. | $104.20 | 2019-2022 | |
| Strongbridge US INC. | $96.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $86.26 | 2019-2022 | |
| Akcea Therapeutics, INC. | $83.35 | 2019-2020 | |
| Aucta Pharmaceuticals, INC. | $78.24 | 2024-2025 | Motpoly Xr |
| Neurelis, INC. | $76.98 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $68.85 | 2021-2025 | Keveyis |
| Merz Pharmaceuticals, LLC | $67.84 | 2025 | Xeomin, Inbrija, Ampyra |
| Zogenix INC. | $66.43 | 2021 | |
| Sunovion Pharmaceuticals INC. | $59.69 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $57.40 | 2022-2025 | Wainua |
| Banner Life Sciences, LLC | $56.80 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $55.74 | 2019-2020 | |
| Tanabe Pharma America, INC. | $54.78 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $48.94 | 2023-2025 | Nuedexta, Rexulti |
| Janssen Biotech, INC. | $45.78 | 2025 | |
| Hospira, INC. | $45.74 | 2025 | |
| Argenx US, INC. | $44.49 | 2024 | Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $42.02 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $39.84 | 2022-2025 | Purified Cortrophin Gel |
| Impel Pharmaceuticals INC. | $39.63 | 2022-2023 | Trudhesa |
| Cycle Pharmaceuticals INC | $38.54 | 2025 | Bafiertam, Tascenso Odt |
| Greenwich Biosciences, INC. | $38.50 | 2021 | |
| Ge Healthcare | $37.07 | 2019-2020 | |
| Nevro Corp. | $32.68 | 2022 | |
| Octapharma USA, INC. | $24.17 | 2024 | Panzyga |
| Abbott Laboratories | $21.57 | 2025 | Infinity |
| Assertio Therapeutics, INC. | $19.64 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.67 | 2025 | Rexulti |
| Averitas Pharma INC. | $18.65 | 2023 | Qutenza |
| Kyowa Kirin, INC. | $17.84 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.00 | 2022 | |
| Upsher-Smith Laboratories LLC | $15.49 | 2021 | |
| Axsome Therapeutics, INC. | $15.00 | 2025 | Symbravo |
| Promius Pharma LLC | $14.08 | 2019 | |
| Zyla Life Sciences, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Warra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.